Date | Price Target | Rating | Analyst |
---|---|---|---|
6/3/2024 | $126.00 → $160.00 | Neutral → Overweight | Piper Sandler |
4/15/2024 | $148.00 → $170.00 | Hold → Buy | Stifel |
3/25/2024 | $117.00 → $160.00 | Equal Weight → Overweight | Wells Fargo |
1/30/2024 | $107.00 → $121.00 | Buy → Hold | Jefferies |
1/3/2024 | Buy → Hold | Needham | |
11/8/2023 | Outperform → Mkt Perform | Raymond James | |
7/18/2023 | $205.00 → $120.00 | Buy → Hold | Stifel |
7/10/2023 | $173.00 | Equal Weight | Wells Fargo |
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
SC 13D/A - MASIMO CORP (0000937556) (Subject)
4 - MASIMO CORP (0000937556) (Issuer)
4 - MASIMO CORP (0000937556) (Issuer)
3 - MASIMO CORP (0000937556) (Issuer)
Piper Sandler upgraded Masimo from Neutral to Overweight and set a new price target of $160.00 from $126.00 previously
Stifel upgraded Masimo from Hold to Buy and set a new price target of $170.00 from $148.00 previously
Wells Fargo upgraded Masimo from Equal Weight to Overweight and set a new price target of $160.00 from $117.00 previously
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
Politan Capital Management (together with its affiliates, "Politan"), a 9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today commented on the outcome of the Company's Annual Meeting of Stockholders (the "Annual Meeting"). Both of Politan's independent nominees – Darlene Solomon and William Jellison – were elected to the Board.1 Politan greatly appreciates the support and engagement from its fellow Masimo shareholders during this process. Darlene Solomon, William Jellison, Michelle Brennan and Quentin Koffey issued the following joint statement: "While each of us is independent and brings our own unique perspectives, we are united in our enthusiasm for
Glass Lewis States That Politan's Nominees Represent a "Clear, Reasoned and Compelling Alternative to the Status Quo" Believes Investors Should Have "Little Confidence" in Existing Board's Ability to Advance Review of Strategic Alternatives Stresses that Politan's Nominees "Would Go a Long Way to Ensuring the Interests of All Investors Are Clearly and Consistently Represented" Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today highlighted that leading proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") has updated its earlier report to reiterate its recommendation that shareho
Highlights Risk to Continued Momentum and Innovation if Politan Gains Board Control Urges Stockholders to Vote "FOR" Only Masimo's Director Nominees, Joe Kiani and Christopher Chavez, on the Updated GOLD Proxy Card Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company's commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company's Board of Direct
Second Quarter 2024 Highlights: Consolidated revenue was $496.3 million; Healthcare revenue was $343.9 million; Non-healthcare revenue was $152.4 million; GAAP net income per diluted share was $0.29; and Non-GAAP net income per diluted share was $0.86. Masimo Corporation (NASDAQ:MASI) today announced its financial results for the second quarter ended June 29, 2024. Second Quarter 2024 Results: Consolidated revenue was $496.3 million, comprised of healthcare revenue of $343.9 million and non-healthcare revenue of $152.4 million. Excluding handheld and fingertip pulse oximeters, shipments of noninvasive technology boards and instruments were 58,600. Consolidated GAAP
Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) Masimo (NASDAQ:MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the cal
8-K - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
DEFA14A - MASIMO CORP (0000937556) (Filer)
- Reuters Citing CNBC
Highlights Quentin Koffey's Actions That Have Flown in the Face of Good GovernanceMasimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI) today highlighted the actions taken by Politan and Quentin Koffey since Masimo's 2023 Annual Meeting of Stockholders that directly contradict their purported commitment to good governance.Over the past twelve months, we believe Politan's Quentin Koffey has repeatedly acted against the best interests of Masimo and its stockholders. The summary provided below shows stockholders and the public the numerous actions Politan has taken to advance its own agenda at the expense of Masimo's governance and stockholder value.
Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors Reaffirms Financial Guidance for Third Quarter 2024 Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates: Leadership Appointments Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareho
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Bob Chapek Joins Masimo's Board of Directors Masimo (NASDAQ:MASI) announced today that Bob Chapek has been appointed to Masimo's Board of Directors. Mr. Chapek was Chief Executive Officer of The Walt Disney Company, one of the world's largest media and entertainment companies, from February 2020 to November 2022, successfully leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and global reach of its streaming services, made transformative changes to its parks and resorts worldwide, and leveraged new and innovative technologies to bring stories to life in more immer